Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series

Cordero-Ruíz, Patricia; Castro-Márquez, Cristina; Méndez-Rufián, Vanesa; Castro-Laria, Luisa; Caunedo-Álvarez, Ángel; Romero-Vázquez, Javier; Herrerías‐Gutiérrez, Juan Manuel

doi:10.4321/s1130-01082011000600003

Cited by 18 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All studies evaluating remission and/or response after primary failure included in the analysis switched from IFX to ADA. Overall remission after primary failure was 30% (175 patients included) (Figure ) . Short‐term remission (18%) was lower than that obtained in the medium (30%) and long term (28%) (Figure ).…”

Section: Resultsmentioning

confidence: 98%

“…The literature search revealed 797 references in Pubmed and 1067 in Embase; however, some references were excluded, among other reasons, for duplication and non‐availability of data on the effectiveness of the second anti‐TNF . Finally, only 46 studies met the inclusion criteria and were included . Of these, 37 focused on CD (Tables S1 and S2), 8 on UC, and 1 on pouchitis (Table S3).…”

Section: Resultsmentioning

confidence: 99%

“…Studies were classified by type of IBD in order to pool data and perform the statistical meta‐analysis; therefore, the pouchitis study was excluded from the meta‐analysis. Of the CD studies, 32 evaluated switching from IFX to ADA, 4 switching from IFX to CZP, and 1 switching from ADA to IFX . All UC studies evaluated switching from IFX to ADA.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

Gisbert

Marín

McNicholl

et al. 2015

Aliment Pharmacol Ther

290

175

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

Gisbert

Marín

McNicholl

et al. 2015

Aliment Pharmacol Ther

290

175

View full text Add to dashboard Cite

show abstract

“…Cordero et al . 17 reported that, in their small-scale clinical study of adalimumab with a 48-week observation period, 2 of a total of 25 patients with CD had serious AEs [tuberculous meningitis and abdominal abscess] during the first 24 weeks of treatment. Moreover, although the study patients were different from those in the present study, Galloway et al 18 reported that, in their study using data from a large-scale patient registry, the risk of serious infections in patients with rheumatoid arthritis receiving anti-TNFα therapy is most commonly noted in the first 24 weeks of treatment.…”

Section: Discussionmentioning

confidence: 99%

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

Ogata

Watanabe

Matsui

et al. 2016

ECCOJC

View full text Add to dashboard Cite

Background and Aims:Data from an all-cases post-marketing study were used to evaluate the safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease [CD].Methods:Patients received adalimumab for 24 weeks. Data from all patients [n = 1693] were used for the safety assessment. Data from patients with CD activity index [CDAI] ≥ 150 at baseline were used for the effectiveness assessment.Results:The most frequent serious adverse drug reaction [ADR] was infection and infestations [6.6 events/100 patient-years]. The risk of serious infections increased in patients who had a history of malignancy and those with concomitant corticosteroid use. Of 415 patients who had switched from another anti-tumour necrosis factor alpha [TNFα] agent to adalimumab due to ADRs, 7.2% discontinued due to ADRs to adalimumab. Ten of 13 patients with a history of tuberculosis [TB] received prophylactic medication, and none developed TB. TB developed in one patient with no history of TB or anti-TB prophylaxis. Remission rates were 41.3% and 32.4% at 4 and 24 weeks, respectively. Remission rates did not differ between patients with and without concomitant use of immunomodulators. Predictive variables for increased effectiveness were CDAI ≤ 220 and disease duration of ≤ 2 years. Perianal lesions and loss of response to previous anti-TNFα agents affected effectiveness.Conclusions:The most frequent serious ADR was infection. Adalimumab significantly reduced disease activity, without any unexpected ADRs. Development of active TB during adalimumab therapy can be prevented through TB screening and prophylaxis. In patients who switched from another anti-TNFα agent to adalimumab due to ADRs, adalimumab was well tolerated.

show abstract

“…In models of experimental colitis, IL-23 rather than IL-12 has been suggested to be the main determinant of chronic intestinal inflammation 29,30…”

Section: Targeting Acute Inflammationmentioning

confidence: 99%

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics

2017

View full text Add to dashboard Cite

Therapy for inflammatory bowel disease (IBD) has changed, with several new agents being evaluated. The era of anti-tumor necrosis factor (anti-TNF) antibody therapy saw remarkable progress in IBD therapy. Some patients, however, do not respond to anti-TNF treatment, or their response decreases over time. This phenomenon highlights the need to identify new molecular targets for therapy in IBD. The targets of new therapeutic molecules in IBD must aim to restore immune dysregulation by the inhibition of proinflammatory cytokines (TNF-α, interleukin [IL]-6, IL-13, IL-17, IL-18, and IL-21) and augmentation of the effect of anti-inflammatory cytokines (IL-10, IL-11, and transforming growth factor β) and to pursue new anti-inflammatory targets, such as regulatory T-cell therapy, Smad7 antisense, Janus-activated kinase inhibition, Toll-like receptor stimulation, leukocyte adhesion, and blockade of T-cell homing via integrins and mucosal addressin cellular adhesion molecule-1. In addition, potential molecular targets could restore mucosal barrier function and stimulate mucosal healing. Despite these potential targets, the value and clinical significance of most new molecules remain unclear, and clinical efficacy and safety must be better defined before their implementation in clinical practice. This article aims to review the promising and emerging molecular targets that could be clinically meaningful for novel therapeutic approaches.

show abstract

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series

Cited by 18 publications

References 16 publications

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

Systematic review with meta‐analysis: the efficacy of a second anti‐TNF in patients with inflammatory bowel disease whose previous anti‐TNF treatment has failed

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics

Contact Info

Product

Resources

About